Interesting article on the benefits of exercise for people with MS. Read article here.
Need help with your PIP?
Citizens Advice offer assistance with information on benefits and tax credits. There is also information about council tax and housing costs, national insurance, payment of benefits and problems with benefits. See their website for more information. https://www.citizensadvice.org.uk/benefits/
ECTRIMS 2015 round up
Source MS Trust
ECTRIMS (European Committee for Treatment and Research In Multiple Sclerosis) hosts the world’s largest conference devoted to basic and clinical research in MS.
This year’s meeting took place in Barcelona from 7-10 October and featured a wide range of presentations, posters and reports of new and on-going research. Read on.
Biogen says multiple sclerosis drug trial for Natalizumab was unsuccessful.
Source Market Watch
Biogen Inc. said Wednesday that a late-stage trial of a drug to treat of secondary progressive multiple sclerosis was unsuccessful. The trial of Natalizumab found that the drug was “well-tolerated” by patients but did not meet its primary and secondary endpoints. “While we’re disappointed with these results, we believe this research will provide the MS community important insights into this more advanced patient population,” said Alfred Sandrock, group senior vice president and chief medical officer at Biogen, in the press release. Shares of Biogen rose 10% Wednesday after the company beat third-quarter earnings expectations
Biogen Inc. said Wednesday that a late-stage trial of a drug to treat of secondary progressive multiple sclerosis was unsuccessful. The trial of Natalizumab found that the drug was “well-tolerated” by patients but did not meet its primary and secondary endpoints. “While we’re disappointed with these results, we believe this research will provide the MS community important insights into this more advanced patient population,” said Alfred Sandrock, group senior vice president and chief medical officer at Biogen, in the press release. Shares of Biogen rose 10% Wednesday after the company beat third-quarter earnings expectations
Study on Biotin for Secondary and Primary Progressive Forms of Multiple Sclerosis
Dr. Daniel Kantor talks about the MD1003 Trial analysis on Biotin for Secondary and Primary Progressive Multiple Sclerosis. Watch here.
Age UK Oxfordshire Exercise Classes
Lots of exercise classes, take a look!
Meditation class
Mobile nail technician
Didcot based mobile nail technician, available to come to your home:
Susan Luker – Nailicious. Specialises in Gelish, Artistic gloss, Smart Gel Polish manicures with Gel Polish, Manicures with ordinary polish, mobile: 07748630273.
Books wanted
The book club has raided £54.65 since it has been running. If you have any recent novels that you can donate to the centre for the club please do.
Relapsing Remitting Multiple Sclerosis
My name is Virginie Louvel and I am a Senior Research Executive at Opinion Health, a London based market research agency.
We are inviting a select number of people who have been diagnosed with Relapsing Remitting Multiple Sclerosis and are currently receiving a disease modifying therapy (DMT) to take part in a national wide project to learn about their treatment preferences and how they take their medicines.
Participation in this research is completely voluntary. All participants who successfully complete the 20-minute online survey will receive an incentive for their time and interest. We have received an ethical approval for this project.
We would be grateful if we could disseminate information about this research to your members.
As a token of appreciation for your help, we will be making a donation to your organisation to support your work in this area.
Opinion Health adheres to BHBIA codes of conduct enduring confidentiality and anonymity to participants in our projects. This research is conducted in accordance with all relevant industry guidelines regarding anonymity, confidentiality, and the ethical practice of healthcare research. All information collected will be used for research purposes only and no answer can be linked to any individual participant.
Looking forward to hearing from you.
Virginie Louvel
Senior Research Executive
Opinion Health
11 Poland Street
London W1F 8QA
